leadf
logo-loader
viewSourceBio International PLC
(
AIM:SBI
)

Source BioScience mark 'eight fold in revenue for company' with 'Covid-19 business the engine'

SourceBio International PLC's (LON:SBI) Jay LeCoque talks to Proactive London's Katie Pilbeam about their 2020 results.

The company reporting strong revenue and profit growth throughout the year driven by its (Coronavirus) COVID-19 antigen testing services and its Infectious Disease Testing business unit, set up last May.

Going forward Jay says 'the Covid-19 business was the engine for the company this past year' and he does not thinking the market for testing is going to go away 'that quickly'. He says airport and sport facility testing is going to be crucial through to 2024.

Quick facts: SourceBio International PLC

Follow
AIM:SBI

Price: 162.5 GBX

Market Cap: £120.55 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

FTSE falls deeper into the sea of red as China induced tsunami hits Asian...

FTSE 100 hit more turbulence as China’s clampdown on tech firms continued to hit Asian markets. In London, the blue chip index shed 48 to 6,976. Tesla profits surged ahead in its latest quarter despite shortages of semiconductor chips and distribution problems. Sales jumped to US$12bn with a...

on 27/7/21

2 min read